HB 3817
Directs the Oregon Health Authority and the Department of Veterans' Affairs to study the consumption of ibogaine by certain individuals for the purpose of treating specified disorders.
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take actionPublic sentiment
Support
50%
Oppose
50%
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Bill overview
This bill directs the Oregon Health Authority (OHA) and the Department of Veterans’ Affairs (DVA) to study the use of ibogaine by certain individuals for treating specific disorders, such as post-traumatic stress disorder, major depressive disorder, anxiety disorders, and substance use disorders. The study will involve establishing a process for ibogaine consumption, requiring screening for cardiac conditions, and establishing a controlled setting for administration. The report on the study must be submitted to the Legislative Assembly by September 15, 2029, and ibogaine consumption through this process will be exempt from the definition of a controlled substance. The bill sunsets on January 2, 2030.
Key provisions
- Directs OHA and DVA to establish a process for ibogaine consumption for specific disorders.
- Requires screening for cardiac conditions prior to ibogaine consumption.
- Mandates a controlled setting for ibogaine administration with a healthcare provider experienced in managing cardiac complications.
- Requires reporting of ibogaine consumption results to OHA and DVA.
- Sets a deadline of September 15, 2029, for submitting a report to the Legislative Assembly.
- Defines ‘ibogaine’ for the purpose of the study.
- Exempts ibogaine consumption through the established process from being classified as a controlled substance.
- The bill sunsets on January 2, 2030.
Who is affected
- Oregon Health Authority (OHA)
- Department of Veterans’ Affairs (DVA)
- Individuals with post-traumatic stress disorder, major depressive disorder, anxiety disorders, and substance use disorders
Sponsors
Official sponsors from legislative records.
Primary sponsors
David Brock Smith
Cosponsors
Arguments in favor
Reasons to support this legislation.
Supporters of the bill believe that it has the potential to provide significant assistance to veterans struggling with traumatic brain injuries, citing evidence from research on ibogaine's efficacy in addressing similar conditions. They argue that the bill's provisions will help ensure access to effective treatment options for this vulnerable population, and that the benefits of ibogaine-based therapy have been demonstrated through studies and clinical trials. Proponents of the bill also emphasize the importance of providing support to veterans who have served in combat zones, highlighting the need for comprehensive care solutions that address the long-term effects of traumatic brain injuries. By passing the bill, supporters hope to improve the lives of these individuals and provide them with the resources they need to recover and reintegrate into civilian life.
Source: Testimony Summaries
Arguments opposed
Reasons to oppose this legislation.
Ibogaine is associated with a significant risk of mortality, with ing alarm over its potential to cause fatal complications. Many experts and advocates emphasize that the lack of rigorous clinical trials and extensive data on Ibogaine's long-term effects render it an unproven treatment for addiction. Furthermore, some critics argue that the substance's potency and potential for abuse raise concerns about its suitability as a therapeutic option, particularly when compared to established treatments with more robust safety profiles.